Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndrome
Congenital heart diseases affect approximately one in 100 patients, making them the most common type of birth defect and the number-one cause of pediatric deaths. Now a new study showing that the mTOR inhibitor drug rapamycin can reverse cardiac muscle damage in a mouse model of the congenital disease LEOPARD syndrome not only identifies the first possible medical treatment for this rare condition, but also demonstrates the importance of targeted therapies in managing congenital diseases.
The research, led by investigators at Beth Israel Deaconess Medical Center (BIDMC), is published in the March issue of the Journal of Clinical Investigation (JCI), which appears on-line today.
"The genetic mutations that alter the signaling pathways involved in cardiac development have been implicated in approximately 30 percent of the defects associated with congenital heart diseases," explains the study's senior author Maria Kontaridis, PhD, a scientist in the Division of Cardiovascular Medicine at BIDMC and Assistant Professor of Medicine at Harvard Medical School. "But the molecular underpinnings of these mutations have not been clear. This new work helps illuminate their complex biochemistry."
Kontaridis's lab investigates LEOPARD syndrome and Noonan syndrome, two of a cluster of congenital diseases known as "RASopathies," which are the result of defects caused by mutations in genes in the RAS signaling pathway.
LEOPARD syndrome affects approximately 200 individuals worldwide and is clinically distinguished by multiple lentigines (freckle-like spots on the skin), as well as craniofacial defects, deafness, and blood abnormalities which can give rise to pediatric leukemias. Hypertrophic cardiomyopathy – a thickening of the heart muscle that typically leads to heart failure – is also associated with LS. With the exception of lentigines, Noonan syndrome patients exhibit nearly identical features and pathologies.
Mutations in the PTPN11 (non-receptor protein tyrosine phosphatase type 11) gene are responsible for virtually all cases of LEOPARD syndrome and about half of the Noonan syndrome cases, notes Kontaridis. Consequently, LEOPARD syndrome [LS] and Noonan syndrome have traditionally been thought to be allelic variants with the same disease etiology.
But, this new study showed that this was not the case. By creating an LS mouse model that reproduced features of the human disorder, the Kontaridis group found that the mutations in PTPN11 that cause LEOPARD syndrome are distinct, and lead to a loss of phosphatase activity and hyperactivation of the AKT/mTOR pathway -- which leads to the development of hypertrophic cardiomyopathy.
"When these mice were treated with rapamycin [an mTOR inhibitor agent best known for its role as an immunosuppressant] the hypertrophic cardiomyopathy was reversed," she explains. "Our next step will be to test rapamycin in a clinical trial to evaluate the effect of this treatment in humans with LEOPARD syndrome. Patients would be enrolled on the basis of biochemical analysis [i.e. mTOR activity] rather than clinical diagnosis."
A related study in today's on-line issue of the JCI, by a team of scientists at the University Health Network, Toronto, found that in a mouse model of Noonan syndrome, excessive activity of an enzyme called ERK (a downstream target of the RAS pathway) led to the development of hypertrophic cardiomyopathy, and that treatment with an ERK inhibitor currently being tested as an anti-cancer agent, reversed the cardiomyopathy. This study was led by UHN scientists Toshiyuki Araki and Benjamin Neel, who was also a co-corresponding author on the Kontaridis paper.
"Together, these two studies demonstrate for the first time that individualized therapy should be considered for patients with RASopathy disorders," says Kontaridis. "Our findings in LEOPARD syndrome may additionally provide the first glimpse of a much broader implication -- a potential mechanism for the treatment of other, more common congenital hypertrophy disorders."
- Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndromefrom Science BlogMon, 21 Feb 2011, 13:30:35 EST
- Study shows rapamycin reverses myocardial defects in mouse model of LEOPARD syndromefrom PhysorgMon, 21 Feb 2011, 12:31:35 EST
Latest Science NewsletterGet the latest and most popular science news articles of the week in your Inbox! It's free!
Learn more about
Check out our next project, Biology.Net
From other science news sites
Popular science news articles
- Relationships with family members, but not friends, decrease likelihood of death
- New device could help improve taste of foods low in fat, sugar and salt
- Hibernating pygmy-possums can sense danger even while dormant
- Pro-nuclear countries making slower progress on climate targets
- Logged rainforests can be an 'ark' for mammals, extensive study shows
- Emergency financial aid from call centers effectively prevents homelessness
- Intermediate HDL cholesterol levels may be best for longevity
- Twenty-five little bones tell a puzzling story about early primate evolution
- Ten trillionths of your suntan comes from beyond our galaxy
- NASA analyzes deadly Louisiana flooding